WHO ICTRP trial
Spermidine Supplementation in polycystic ovary syndrome
IRCT20221109056451N6 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20221109056451N6 |
|---|---|
| Public title | Spermidine Supplementation in polycystic ovary syndrome |
| Scientific title | The Synergistic Impact of Spermidine Supplementation and Midwifery Counseling on Hormonal Balance and Psychological Well-being in Women with polycystic ovary syndrome: A randomized blinded clinical trial |
| Primary sponsor | Babol University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Polycystic ovary syndrome. Polycystic ovarian syndrome;E28.2 |
| Interventions | Intervention 1: Thirty-six women will receive structured midwifery counseling (four weekly sessions, each lasting 30–45 minutes, conducted via WhatsApp/Google Meet) together with daily oral spermidine supplementation for eight weeks.The… |
| Registration date | Oct 27, 2025 |
| Target size | 72 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: